How do I buy Galectin Therapeutics Inc. Common Stock (GALT) stock?

Buying Galectin Therapeutics Inc. Common Stock (GALT) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and complete KYC. Make a deposit. Search for the code "GALT", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy GALT by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

How do I tell if GALT is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Galectin Therapeutics Inc. Common Stock (GALT) Stock

Q: What is the minimum investment for GALT on Gotrade?

On Gotrade , you don't have to buy a full lot. With fractional shares, you can start investing in Galectin Therapeutics Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

NASDAQ · GALT

Trade GALT

Key stats

Market cap: $316.67M
Price / Earnings ratio: -10.7x
EPS (TTM): -$0.43
Volume: Loading
52-week high: $7.13
52-week low: $2.03

Source: third-party data provider, as of November 10, 2026

Compare with GALT

Technical indicators

RSI 14: 39.77
MACD 12/26/9: -0.14
EMA 9 of MACD: -0.12
MACD histogram: -0.02
SMA 50: $3.74; Price below SMA 50
EMA 50: $3.57; Price below EMA 50
SMA 200: $3.21; Price below SMA 200
EMA 200: $3.57; Price below EMA 200

Calculated by Gotrade from daily closing prices, as of November 6, 2026. Technical data, not a recommendation.

Analyst ratings

No analyst data available

Financials

Performance

Revenue

Net income

Net margin %

2021

2022

2023

2024

2025

0000

Debt & Balance Sheet

Total assets

Total liabilities

2021

2022

2023

2024

2025

175M115M58M0

Revenue to Profit

2025

$0.0

Revenue

$0.0

Cost of revenue

$0.0

Gross profit

$0.0

Operating expenses

$-30.8M

Net income

Earnings

No data available

Source: third-party data provider

About Galectin Therapeutics Inc. Common Stock

No description available.

SectorHealthcare

IndustryBiotechnology

Employees9

IPO DateSep 9, 2002

HeadquartersNorcross, GA

Key Executives

Name	Title	Year Born
Dr. Khurram Jamil M.D.	Chief Medical Officer	1976
Mr. Robert Tritt J.D.	General Counsel	—
Mr. Jim Wilkins Ph.D.	Head of CMC & Pharmaceutical Development	—
Ms. Beth Knowles	Executive Assistant & Officer Manager	—

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021											-10.8	-14.5
2022	-16.5	-11.8	-13.9	-1.9	-17.8	-19.1	+72.5	-16.3	-10.9	-16.9	-8.6	-8.9
2023	-1.7	+80.0	+2.4	-9.3	-8.2	-9.4	+4.2	+25.0	+9.1	+6.3	-3.0	-17.0
2024	-2.9	+12.6	+23.8	+43.9	-22.3	-16.0	+6.4	+20.5	+10.0	-9.2	+15.6	-53.9
2025	+6.8	+27.6	-18.1	+8.7	+0.8	+63.6	+64.0	+17.3	-4.1	+39.0	-4.5	-24.5
2026	-30.1	-0.7	-8.8	-15.3	+11.0	+77.8	-31.4	+30.4	-7.0	-11.7	-5.7

Stocks in the same sector

Vertex Pharmaceuticals

ABEO

Abeona Therapeutics Inc.

FAQ

Buying Galectin Therapeutics Inc. Common Stock (GALT) stock is now easy and instant through the Gotrade app.

Download the Gotrade app from the App Store or Google Play.
Create an account and complete KYC.
Make a deposit.
Search for the code "GALT", then tap "Trade".
Tap the "Buy" button.
Enter the amount you want to buy. You have two options:
1. Buy GALT by number of shares.
2. Buy fractional shares in dollars, starting from $1.
Swipe up to confirm your order, and you're done!

On Gotrade, you don't have to buy a full lot. With fractional shares, you can start investing in Galectin Therapeutics Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

At the moment, Galectin Therapeutics Inc. Common Stock (GALT) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track GALT's performance via the price chart in the Gotrade app.

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

You can place orders 24/7. Transactions will be executed when the US market (NYSE/NASDAQ) is open, from 9:30 PM to 4:00 AM WIB, or 8:30 PM to 3:00 AM WIB during Daylight Saving Time. Gotrade also provides access to pre-market and after-hours trading, so you have more flexibility and aren't limited to regular working hours.

Market hours may change due to daylight saving time and holidays. In Gotrade, you can see the market status (open/closed) directly in the app.

There's no single perfect answer, but common approaches include:

Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
Review revenue and earnings growth.
Check margins and cash flow.
Evaluate business outlook and the company's position within its industry.

You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Trade Faster. Easier. Smarter.

#ReadyGoTrade

Welcome Reward up to $1,888

Create an account and trade US stocks on Gotrade

Download app

*Terms & conditions apply

Galectin Therapeutics Inc. Common Stock (GALT) Stock

Key stats

Compare with GALT

Recent news

GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH

GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH

GALT Stock Surges 22% — On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial

GALT Stock Surges 22% — On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial

Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock?

Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock?

GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with The Schall Law Firm

GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with The Schall Law Firm

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH

GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH

GALT Stock Surges 22% — On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial

GALT Stock Surges 22% — On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial

Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock?

Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock?

GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with The Schall Law Firm

GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with The Schall Law Firm

Why Did GALT Shares Plummet Over 30% Today?

Why Did GALT Shares Plummet Over 30% Today?

About Galectin Therapeutics Inc. Common Stock

Key Executives

Fundamentals

Valuation

Profitability

Trading

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade